U.S. Markets open in 32 mins

How Is Merck’s Cardiovascular Portfolio Positioned after H1 2018?

Daniel Collins
How Is Merck’s Cardiovascular Portfolio Positioned after H1 2018?

In the second quarter of 2018, Merck’s (MRK) Zetia generated revenues of $226.0 million compared to $367.0 million in the second quarter of 2017, reflecting a ~38% year-over-year (or YoY) decline and a ~26% sequential decline. In the second quarter of 2018, in the US and international markets (outside the US markets), Zetia generated revenues of $8.0 million and $218.0 million, respectively, compared to $122.0 million and $246.0 million in the second quarter of 2017.